Insmed Inc (INSM)

[coinstarz]

Right on abharploonta...

So, from TRCA's perspective, just having a suit on file is sufficient to meet the needs of their strategy in this area.

Insmed does change its marketing strategy accordingly. Sales people concentrate that iPlex is once-daily shut and high Growth Velocity (GV) over other Mecasermin drugs. They are using FDA data to sell iPlex. iPlex selling is much better than Increlex. Many patients like one shut daily vs. twice daily. Patients care about physical pain more than safety issues but doctors think about safety first all the time. Either way, iPlex has both that patients and doctors like.